TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04510896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InheRET
Description: Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Acceptance
Description: Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Acceptance Survey
Description: Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
Study: NCT02807688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Intervention
Description: The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer.
Study: NCT02082730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASARM
Description: The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASARM
Description: The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
Study: NCT03085745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
Study: NCT00088894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00465647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
Study: NCT03476369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90Mg Tablet
Description: Ticagrelor administered crushed vs non-crushed
Study: NCT01649375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab 75 mg s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00568087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take oral placebo (identical matching placebo) during the study period.
Study: NCT00465647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
Study: NCT02804035

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sc2Wear Furosemide
Description: Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
Study: NCT01649375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab 150 mg s.c.
Study: NCT03940391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and midazolam
Description: Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
Study: NCT04016077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 30 mg
Description: PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 30 mg
Description: PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 30 mg
Description: PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
Study: NCT00820001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Treatment
Description: Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No-Booster
Description: All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: All cases assigned to this arm simply participated in all of the proposed routine assessments.
Study: NCT01859507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
Study: NCT02148120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04224597

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: all participants will be determined by ultrasonography.
Study: NCT02781168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of earmuffs
Description: The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of earmuffs
Description: The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
Study: NCT04213768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral rectus plication
Description: The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral rectus Resection
Description: Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
Study: NCT03090698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: intra-articular administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: intra-articular administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intra-articular administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intra-articular administration
Study: NCT01324648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-supported self-help and GP treatment as usual
Description: Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupported self-help and GP treatment as usual
Description: This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General practitioner treatment as usual
Description: This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
Study: NCT03488498

Intervention type: OTHER
Intervention: questionnaires
Description: Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.

Intervention type: OTHER
Intervention: questionnaires
Description: Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.

Intervention type: OTHER
Intervention: questionnaires
Description: Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
Study: NCT03328351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: 1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Superficial soft tissue massage
Description: 1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times
Study: NCT02711007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
Study: NCT02106403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prototype disinfectant spray formulation
Description: 0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: 0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative control
Description: 0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
Study: NCT03511157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: See Ischemic Preconditioning Experimental group description

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: See Control group description
Study: NCT01939639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal application, sodium chloride solution, 3 puffs per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU Oxytocin, intranasal application 45 min prior to the experiment
Study: NCT01496846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IANB Articaine
Description: IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IANB Articaine
Description: IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IANB Articaine
Description: IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUP Articaine
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUP Lidocaine
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
Study: NCT02128880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARRII
Description: CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CARRII Education
Description: CARRII Education provides information on women's health related to drinking and contraception in a static website format.
Study: NCT04429724

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test Covid-19
Description: Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
Study: NCT02452450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Lysine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Liquid Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study: NCT02622893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic nephrectomy
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retroperitoneal laparoscopic nephrectomy
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
Study: NCT04552106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x3/day
Description: 3 capsules 3 times daily for 28 days
Study: NCT02008448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear Lesion Ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear Lesion Ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BT injection
Study: NCT04091646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Foam 0.3%
Description: Roflumilast foam for topical application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Vehicle foam for topical application.
Study: NCT02224911

Intervention type: DEVICE
Intervention: Laser Interstitial Thermal Therapy
Study: NCT02606591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalograph
Description: EEG performed at beginning and end of school year.